This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cosette Pharmaceuticals, Inc. By combining Cosettes strong portfolio with Mayne Pharmas proven commercial expertise, the combined company will be well positioned to further invest in innovation, portfolio expansion and better serve our patients. is acquiring Mayne Pharma.
Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical. the venture capital organization of Johnson & Johnson.
Verrica Pharmaceuticals Inc.’s While NCE status will provide YCANTH with a minimum of five years of protection, we anticipate our full patent portfolio to provide protection from generic competition for the next decade and potentially beyond,” says Ted White, Verrica’s President and Chief Executive Officer, in a news release.
million people through Almirall’s dermatology portfolio by 2030. Recently, Almirall was rated as one of the top 5% of companies in the pharmaceutical industry by Sustainalytics. Ecovadis recognized Almirall with a platinum medal, placing it in the top 1% of evaluated pharmaceutical companies for sustainability.
On today’s program we are going to talk about a couple of beauty industry news stories and answer your questions about… Is an expensive skin serum worth the money even it if is from a pharmaceutical company? They are selling “wearable nutrition” as part of their Thrive product portfolio. Do nutrition pads work to deliver actives?
Is it merely a diversification of portfolios or a genuine interest in promoting health? Brands like Centrum, Nature Made, and One-A-Day have also been enveloped by global giants like Glaxo Smith Kline, Otsuka Pharmaceuticals, and Bayer. Moreover, it's not just Nestlé.
In Reckitt Benckiser’s Legal department, Meredith developed claims testing protocols, supported NAD challenges, and was responsible for legal approval of all claims and advertising materials for the Health & Hygiene portfolios including Mucinex, Delsym, Air Wick, Lysol, Veet, Clearasil, Durex, among many others.
Dr M has over 20 years of experience in the pharmaceutical, biopharma and cosmetics industries. His product safety portfolio included: Jergens and Curel lotions, Biore face care, Ban antiperspirant, and John Frieda hair care. Mojgan Moddaresi (Aka DrM) is a regulatory expert and managing director of personal Care Regulatory ltd.
Her work has been featured in international publications including New York Times and Chemical & Engineering News John's Slides John Stanton comes from a background of 60 years of experience in the pharmaceutical and health care industries, mostly spent in R & D related roles.
Moreover, Glenmark Pharmaceuticals received manufacturing and marketing approval for the Nitric Oxide Nasal Spray (NONS) as part of an accelerated approval process. Glenmark Pharmaceuticals has signed a partnership with Canadian company SaNOtize Research & Development Corp., You can purchase it online on Amazon.com.
and Kaken Pharmaceutical Co., ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions. The post ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan appeared first on The Dermatology Digest. Alumis Inc.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content